サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1435150

抗けいれん薬市場：薬物タイプ別、適応症別-2024-2030年の世界予測

Anticonvulsants Market by Drug types (AMPA, Barbiturate, Benzodiazepine), Indication (Anxiety, Bipolar Disorder, Borderline Personality Disorder) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 192 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗けいれん薬市場：薬物タイプ別、適応症別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗けいれん薬市場規模は2023年に120億3,000万米ドルと推計され、2024年には130億7,000万米ドルに達し、CAGR 8.71%で2030年には215億9,000万米ドルに達すると予測されます。

抗けいれん薬の世界市場

主な市場の統計
基準年[2023］ 120億3,000万米ドル
予測年[2024] 130億7,000万米ドル
予測年 [2030] 215億9,000万米ドル
CAGR（%） 8.71%
抗けいれん薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗けいれん薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、抗けいれん薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-抗けいれん薬市場の市場規模および予測は？

2-抗けいれん薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-抗けいれん薬市場における技術動向と規制の枠組みは？

4-抗けいれん薬市場における主要ベンダーの市場シェアは？

5-抗けいれん薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 若者と高齢者の間でてんかんの有病率が増加
      • てんかんに対する意識を支援する政府の取り組みの高まり
      • 非てんかん疾患の治療における使用の拡大
    • 抑制要因
      • 疼痛管理のための代替品の選択肢の利用可能性
    • 機会
      • 規制当局による抗けいれん薬の承認の増加
      • 新世代抗てんかん薬の登場
    • 課題
      • 医薬品の供給不足と第二世代医薬品の特許切れ
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 抗けいれん薬市場薬剤の種類別

  • アンパ
  • バルビツレート
  • ベンゾジアゼピン
  • カーバメート抗けいれん薬
  • 炭酸脱水酵素阻害剤
  • ジベンザゼピン
  • トリアジン

第7章 抗けいれん薬市場適応症別

  • 不安
  • 双極性障害
  • 境界性人格障害
  • てんかん
  • 線維筋痛症
  • 片頭痛
  • 神経因性疼痛

第8章 南北アメリカの抗けいれん薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の抗けいれん薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの抗けいれん薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • Astrazeneca PLC
    • Bausch Health Companies Inc.
    • Biocon Limited
    • Cadila Pharmaceuticals Limited
    • Cipla, Inc.
    • Dr. Reddy's Laboratories Limited
    • Eisai Co., Ltd.
    • GlaxoSmithKline PLC
    • Glenmark Pharmaceuticals Ltd.
    • Jazz Pharmaceuticals, Inc.
    • Johnson & Johnson Services, Inc.
    • Lifecare Neuro Products Limited
    • Lundbeck A/S
    • Mankind Pharma Ltd.
    • Merck KGaA
    • Novartis AG
    • Novo Nordisk A/S
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • Sanofi S.A.
    • Sunovion Pharmaceuticals Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Wockhardt Limited
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTICONVULSANTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTICONVULSANTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTICONVULSANTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTICONVULSANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTICONVULSANTS MARKET DYNAMICS
  • FIGURE 7. ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2030 (%)
  • FIGURE 8. ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTICONVULSANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 6. ANTICONVULSANTS MARKET SIZE, BY AMPA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 41. CHINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 43. INDIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 45. INDONESIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 47. JAPAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 49. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 51. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 53. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 55. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 57. TAIWAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 59. THAILAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 61. VIETNAM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 66. DENMARK ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 68. EGYPT ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 70. FINLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 72. FRANCE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 74. GERMANY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 76. ISRAEL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 78. ITALY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 80. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 82. NIGERIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 84. NORWAY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 86. POLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 88. QATAR ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 90. RUSSIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 92. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 96. SPAIN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 98. SWEDEN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 100. SWITZERLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 102. TURKEY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 108. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 109. ANTICONVULSANTS MARKET LICENSE & PRICING
目次
Product Code: MRR-ED54C46E805C

[192 Pages Report] The Anticonvulsants Market size was estimated at USD 12.03 billion in 2023 and expected to reach USD 13.07 billion in 2024, at a CAGR 8.71% to reach USD 21.59 billion by 2030.

Global Anticonvulsants Market

KEY MARKET STATISTICS
Base Year [2023] USD 12.03 billion
Estimated Year [2024] USD 13.07 billion
Forecast Year [2030] USD 21.59 billion
CAGR (%) 8.71%
Anticonvulsants Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anticonvulsants Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anticonvulsants Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anticonvulsants Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astrazeneca PLC, Bausch Health Companies Inc., Biocon Limited, Cadila Pharmaceuticals Limited, Cipla, Inc., Dr. Reddy's Laboratories Limited, Eisai Co., Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Jazz Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Lifecare Neuro Products Limited, Lundbeck A/S, Mankind Pharma Ltd., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Wockhardt Limited.

Market Segmentation & Coverage

This research report categorizes the Anticonvulsants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug types
    • AMPA
    • Barbiturate
    • Benzodiazepine
    • Carbamate Anticonvulsants
    • Carbonic Anhydrase Inhibitor
    • Dibenzazepine
    • Triazine
  • Indication
    • Anxiety
    • Bipolar Disorder
    • Borderline Personality Disorder
    • Epilepsy
    • Fibromyalgia
    • Migraine
    • Neuropathic Pain
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anticonvulsants Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anticonvulsants Market?

3. What are the technology trends and regulatory frameworks in the Anticonvulsants Market?

4. What is the market share of the leading vendors in the Anticonvulsants Market?

5. Which modes and strategic moves are suitable for entering the Anticonvulsants Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Anticonvulsants Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of epilepsy among young and senior population
      • 5.1.1.2. Rising government initiatives supporting epilepsy awareness
      • 5.1.1.3. Expanding use in treating nonepileptic conditions
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of substitutes options for pain management
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
      • 5.1.3.2. Emergence of new-generation antiepileptic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Drug supply shortage and patent expiration of the second-generation drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Anticonvulsants Market, by Drug types

  • 6.1. Introduction
  • 6.2. AMPA
  • 6.3. Barbiturate
  • 6.4. Benzodiazepine
  • 6.5. Carbamate Anticonvulsants
  • 6.6. Carbonic Anhydrase Inhibitor
  • 6.7. Dibenzazepine
  • 6.8. Triazine

7. Anticonvulsants Market, by Indication

  • 7.1. Introduction
  • 7.2. Anxiety
  • 7.3. Bipolar Disorder
  • 7.4. Borderline Personality Disorder
  • 7.5. Epilepsy
  • 7.6. Fibromyalgia
  • 7.7. Migraine
  • 7.8. Neuropathic Pain

8. Americas Anticonvulsants Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anticonvulsants Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anticonvulsants Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Abbott Laboratories
    • 12.1.2. Astrazeneca PLC
    • 12.1.3. Bausch Health Companies Inc.
    • 12.1.4. Biocon Limited
    • 12.1.5. Cadila Pharmaceuticals Limited
    • 12.1.6. Cipla, Inc.
    • 12.1.7. Dr. Reddy's Laboratories Limited
    • 12.1.8. Eisai Co., Ltd.
    • 12.1.9. GlaxoSmithKline PLC
    • 12.1.10. Glenmark Pharmaceuticals Ltd.
    • 12.1.11. Jazz Pharmaceuticals, Inc.
    • 12.1.12. Johnson & Johnson Services, Inc.
    • 12.1.13. Lifecare Neuro Products Limited
    • 12.1.14. Lundbeck A/S
    • 12.1.15. Mankind Pharma Ltd.
    • 12.1.16. Merck KGaA
    • 12.1.17. Novartis AG
    • 12.1.18. Novo Nordisk A/S
    • 12.1.19. Otsuka Pharmaceutical Co., Ltd.
    • 12.1.20. Pfizer Inc.
    • 12.1.21. Sanofi S.A.
    • 12.1.22. Sunovion Pharmaceuticals Inc.
    • 12.1.23. Takeda Pharmaceutical Company Limited
    • 12.1.24. Teva Pharmaceutical Industries Ltd.
    • 12.1.25. Wockhardt Limited
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing